GlassScriptPhysician profile
Valesia Phillips
NPI 1225080625
$3,634.81
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $1,559 · 2021: $583.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $379.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $362.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $309.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.94 | 2019-2021 | |
| Novo Nordisk INC | $298.48 | 2019-2021 | |
| Amgen INC. | $275.92 | 2019-2021 | |
| Lilly USA, LLC | $262.79 | 2019-2021 | |
| Pfizer INC. | $246.68 | 2019-2021 | |
| Astellas Pharma US INC | $161.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $154.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $142.50 | 2019-2021 | |
| Abbvie INC. | $113.85 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $105.13 | 2019-2020 | |
| Allergan, INC. | $71.98 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $70.19 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $68.16 | 2019-2021 | |
| Amarin Pharma, INC. | $60.86 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $58.04 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.60 | 2019-2020 | |
| Abbott Laboratories | $35.64 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $30.92 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.63 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $21.88 | 2019 | |
| Avion Pharmaceuticals | $14.68 | 2020 | |
| Hikma Pharmaceuticals USA | $12.25 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valesia Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.